Daiichi Sankyo: ENHERTU Approved in the EU for Patients with

Approval broadens indication for Daiichi Sankyo and AstraZeneca's ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results

Related Keywords

United States , China , Japan , America , Masashi Kawase , Daiichi Sankyo , Daiichi Sankyo Europe Gmb , Simone Jendsch Dow , Daiichi Sankyo Inc , Daiichi Sankyo Company , European Commission , Clinical Development Program , Nasdaq , Sustainable Development Of Society , Daiichi Sankyo Co Ltd , Astrazeneca , Committee For Medicinal Products Human , European Union , Innovative Global Healthcare Company , Medicinal Products , Human Use , New England Journal , North America , Breakthrough Therapy Designation , Sankyo Company , Global Healthcare Company Contributing , Sustainable Development , Pathol Transl , Sankyo Europe Gmbh , Daiichi , Sankyo , Enhertu , Approved , Patients , Ther2 , Positive , Metastatic , Breast , Dancer , Reated , More , Rior , Anti , Ased , Regimens ,